Renaissance Technologies
XLO icon

Renaissance Technologies’s Xilio Therapeutics XLO Stock Holding History

Renaissance Technologies’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Buy
49,566
+24,965
+101% +$204K ﹤0.01% 2672
2025
Q4 		$220K Buy
24,601
+9,980
+68% +$105K ﹤0.01% 2862
2025
Q3 		$173K Buy
14,621
+2,892
+25% +$29K ﹤0.01% 3159
2025
Q2 		$112K Sell
11,729
-964
-8% -$10.2K ﹤0.01% 3283
2025
Q1 		$129K Sell
12,693
-8,494
-40% -$107K ﹤0.01% 3154
2024
Q4 		$283K Buy
21,187
+2,166
+11% +$29.8K ﹤0.01% 3061
2024
Q3 		$210K Sell
19,021
-2,050
-10% -$25.2K ﹤0.01% 3111
2024
Q2 		$280K Buy
21,071
+3,253
+18% +$50.9K ﹤0.01% 2935
2024
Q1 		$269K Buy
17,818
+2,839
+19% +$27.4K ﹤0.01% 3129
2023
Q4 		$115K Buy
14,979
+13,500
+913% +$267K ﹤0.01% 3271
2023
Q3 		$44K Buy
1,479
+29
+2% +$1.08K ﹤0.01% 3425
2023
Q2 		$53K Buy
1,450
+107
+8% +$4.55K ﹤0.01% 3607
2023
Q1 		$60K Sell
1,343
-1,307
-49% -$57.4K ﹤0.01% 3619
2022
Q4 		$100K Buy
2,650
+614
+30% +$20.7K ﹤0.01% 3617
2022
Q3 		$83K Sell
2,036
-3,343
-62% -$130K ﹤0.01% 3651
2022
Q2 		$220K Buy
+5,379
New +$285K ﹤0.01% 3611

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Renaissance Technologies's XLO Position: Q1 2026 in Review

Renaissance Technologies increased its Xilio Therapeutics (XLO) stake by 101% in Q1 2026, buying an estimated $204K and bringing the position to 49,566 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #2672.

Renaissance Technologies first reported a position in XLO in Q2 2022 and has held it in 16 quarters since. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Renaissance Technologies held 49,566 shares of Xilio Therapeutics worth $417K as of Q1 2026.
  • Renaissance Technologies bought 24,965 Xilio Therapeutics shares in Q1 2026, an estimated $204K.
  • Xilio Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2672 holding.
  • Renaissance Technologies first reported a position in Xilio Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.